Alsulihem and Corcos (2020) examined the available literature to evaluate the safety, efficacy, and outcomes of lasers in the treatment of female SUI and OAB. PubMed search was performed up to May 2020, including observational and investigational human studies that documented the effects on laser treatment in SUI and OAB. A total of 27 studies, recording subjective or objective measures in SUI or OAB were included. Lasers used included Er:YAG and Fractional CO2 lasers. The overall quality of studies was poor, and 23/27 studies were case-series studies (Level of evidence [LOE] = 4). Er:YAG laser showed a modest reduction in mild SUI cases, with benefits lasting a maximum of 13 to 16 months. Er:YAG laser for OAB showed conflicting results, with a trend to improve OAB symptoms for up to 12 months. Fractional CO2 laser showed an improvement of mild SUI in few studies; however, no long-term data are available. For OAB symptoms, studies showed minimal improvement that was examined in short-term studies. When reported, AEs were insignificant, however, they were not reported systematically. Several drawbacks have been noticed in the current literature of vaginal lasers, including large variation in laser settings and protocols, short-term follow-up, lack of urodynamic evaluation, and appropriate objective measures. The authors concluded that based on the available literature, lasers cannot be recommended as a therapeutic option at this time. These researchers stated that future better-quality studies are needed to document the exact mechanism of action, longevity, safety and its eventual place into the current treatment algorithms of SUI and OAB.